Meet Ideogen at EHA2027 in Barcelona, 10–13 June, to discuss the latest advances in malignant haematology, cell therapies and transplantation.
Ideogen will be present at EHA2027 in Barcelona to discuss the latest advances in malignant haematology, cell therapies and stem cell transplantation with the European haematology community. The EHA2027 Congress takes place from 10–13 June 2027 at Fira Barcelona Gran Via, in a hybrid format combining in-person and online attendance.[1]
EHA is the largest haematology congress on the European calendar and the most comprehensive forum for the field. For Ideogen, Barcelona is an opportunity to exchange perspectives with haematologists, transplant physicians, cellular therapy specialists, nurses, pharmacists and researchers on the science shaping oncohaematology.
Our participation will centre on informed, non-promotional scientific discussion—not individual products or treatment recommendations.
The EHA Congress is the single gathering where benign and malignant haematology, translational science and clinical practice meet at full European scale. The 2026 edition in Stockholm welcomed more than 14,000 delegates on site, with the hybrid format extending participation further.[2]
The scientific breadth is equally significant: the 2026 congress received a record-breaking 4,700+ abstract submissions and offered over 575 scientific sessions and presentations, selected through international peer review.[3] EHA’s own anniversary review underlines the format’s continuity: a consolidated blend of plenary sessions, sponsored sessions and two poster sessions distributed across all four congress days.[1]
For a company focused on oncohaematology and cellular therapy, EHA is where the evidence base for the coming year is set—and where the questions specialists are asking become visible early.
Oncohaematology is Ideogen’s therapeutic area: the treatment of cancers of the blood, bone marrow and lymphatic system. Its scale is substantial. Analysis of GLOBOCAN 2022 data across 185 countries estimates that haematological malignancies accounted for 6.6% of all new cancer cases and 7.2% of cancer-related deaths worldwide, with the lifetime risk of developing a haematological malignancy at 1.67%—highest for non-Hodgkin lymphoma (0.73%), followed by leukaemia (0.60%), multiple myeloma (0.27%) and Hodgkin lymphoma (0.08%).[2a]
These cancers span dozens of distinct disease entities, many of them rare. That heterogeneity is precisely why a forum covering the full spectrum of malignant haematology matters: advances in one entity inform the management of others, and rare subtypes progress fastest when the field meets at scale.
Within oncohaematology, Ideogen’s scientific work concentrates on conditions where treatment options remain limited: relapsed or refractory T-cell lymphomas, myeloid malignancies such as acute myeloid leukaemia and myelodysplastic syndromes, acute lymphoblastic leukaemia, and the transplant and cellular-therapy pathway—from conditioning before allogeneic stem cell transplantation to recovery of the haematopoietic system. These areas shape which EHA sessions our teams will prioritise.
EHA’s programme spans leukaemias, lymphomas, myeloma and myeloproliferative neoplasms, alongside advances in diagnostics and supportive care. The EHA2027 programme structure includes plenary sessions, thematic debates, educational sessions and late-breaking abstracts, with the opening ceremony and plenary abstracts session anchoring each congress edition.[1]
We are particularly interested in how emerging data are interpreted: the length of follow-up, the differences between trial populations and routine-practice patients, and where genuine practice change is still emerging rather than established.
Cellular and gene-based approaches now feature throughout the EHA programme, from laboratory science to late-phase clinical data. EHA2026’s own retrospective captured this trajectory—AI-enabled drug development, cellular therapies and novel targeted strategies described as defining “the future of haematology”.[2]
In Barcelona, we will look to discuss the latest advances in cell therapies and transplantation in oncohaematology: how transplant and cellular therapy pathways are evolving, how sequencing questions are being framed, and how teams assess durability, safety and recovery after treatment.
These discussions sit naturally alongside the specialist transplant focus of EBMT. Where EBMT concentrates on transplantation and cellular therapy specifically, EHA sets the broader malignant-haematology context in which those decisions are made.
Scientific progress only matters if it reaches patients. The 2026 congress review noted EHA’s active engagement in access and evaluation discussions across Europe, including engagement with health-technology-assessment processes and regulatory science.[3] How innovations move from abstract to accessible care differs substantially between health systems, and those differences are a legitimate scientific conversation in their own right.
We look forward to exchange on referral pathways, centre coordination, evidence generation in routine practice and the operational realities of specialist haematology services.
EHA’s published deadlines for Barcelona:[1]
Programme details, session formats and speaker lists remain provisional until EHA publishes the final schedule and remain subject to change.
Ideogen will be present in Barcelona throughout the congress and looks forward to meeting the haematology community—specialists, transplant teams, researchers and allied professionals alike. We welcome scientific conversation on the advances that matter most to delegates, in malignant haematology, cellular therapy and transplant care.
If you are attending EHA2027—onsite in Barcelona or through the hybrid platform—we would welcome the opportunity to connect with the Ideogen team during the meeting.
